Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Mesoblast LimitedNASDAQ: MESO
Cash & Equivalents · Q4 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 36.1% from a year ago
Cash & equivalents stood at $102.91M at the end of Q4 FY2026, down 36.1% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -12.6% a year.
Context
- Cash & equivalents amounted to 13.3% of total assets at the end of Q4 FY2026, down 7.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -36.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 47.39M USD
- Year-over-year change
- -70.6%
- 4-year CAGR
- -5.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 47.39M | -70.6% |
| FY2025 | 2025-06-30 | 161.16M | +157.6% |
| FY2024 | 2024-06-30 | 62.56M | -11.8% |
| FY2023 | 2023-06-30 | 70.92M | +18.1% |
| FY2022 | 2022-06-30 | 60.03M | — |
Cash & Equivalents vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's Jun 2026 cash & equivalents of $102.91M is the 3rd highest of the 6 companies compared; the peer median is $39.57M.
- Its year-over-year change of -36.1% is the lowest of 6, against a peer median of +65.2%.
- Cash & equivalents amounts to 13.3% of total assets for MESO, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $460.7M | +65.2% | +4.7% | 27.4% | |
| Mar 2026 | $105.42M | +266.1% | +210.6% | 32.3% | |
| Jun 2026 | $102.91M | -36.1% | -12.6% | 13.3% | |
| Mar 2026 | $39.57M | -11.9% | -8.7% | 13.9% | |
| Mar 2026 | $35.94M | -24.9% | +53.2% | 32.8% | |
| Dec 2025 | $6.18M | +736.7% | -23.8% | 5.8% | |
| Peer median (excluding MESO) | $39.57M | +65.2% | +4.7% | 27.4% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.03M | 70.92M | 62.56M | 161.16M | 47.39M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.4M | 7M | 20.95M | 14.87M | 57.66M |
| Inventory | 0 | 0 | 0 | 22.25M | 28.11M |
| Other Current Assets | 413K | 398K | 397K | 393K | 55.52M |
| Total Current Assets | 69.84M | 81.66M | 86.46M | 204.35M | 197.49M |
| Property, Plant & Equipment (Net) | 9.97M | 6.49M | 3.84M | 5.82M | 8.01M |
| Goodwill | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M |
| Intangible Assets | 444.2M | 442.73M | 441.28M | 437.37M | 431.92M |
| Long-term Investments | 1.76M | 1.76M | 1.01M | 1.39M | 0 |
| Tax Assets | 252K | 1.85M | 0 | 0 | 0 |
| Other Non-current Assets | 1.68M | 481K | 2.1M | 1.3M | 1.2M |
| Total Non-current Assets | 592.31M | 587.76M | 582.69M | 580.33M | 575.59M |
| Total Assets | 662.14M | 669.42M | 669.15M | 784.68M | 773.08M |
| Account Payables | 23.08M | 20.15M | 7.07M | 19.08M | 34.51M |
| Short-term Debt | 5.02M | 5.95M | 13.86M | 54.16M | 10.6M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 17.91M | 6.4M | 0 | 0 | 0 |
| Other Current Liabilities | 2.19M | 5.43M | 49.69M | 26.71M | 20.68M |
| Total Current Liabilities | 51.37M | 41.98M | 73.24M | 102.63M | 81.11M |
| Long-term Debt | 91.62M | 102.81M | 100.48M | 67.74M | 108.64M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 15.02M | 19.11M | 13.12M | 13.29M | 9.86M |
| Total Non-current Liabilities | 113.73M | 125.6M | 115.56M | 84.62M | 123.56M |
| Total Liabilities | 165.1M | 167.58M | 188.8M | 187.24M | 204.67M |
| Common Stock | 1.17B | 1.25B | 1.31B | 1.51B | 1.53B |
| Retained Earnings | (738.92M) | (820.81M) | (908.76M) | (1.01B) | (1.07B) |
| Accumulated OCI | 70.65M | 73.52M | 78.3M | 99.5M | 106.03M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 497.04M | 501.84M | 480.36M | 597.44M | 568.41M |
| Total Debt | 106.91M | 116.5M | 118.92M | 128.16M | 127.33M |
| Net Debt | 46.87M | 45.58M | 56.36M | (33M) | 79.94M |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.